 IRVINE, Calif., April 18, 2022 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets Eighteenth Annual Investor Conference on Thursday, April 21st at 11:30 a.m. ET. 